Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)

Fasching, P. A.Bardia, A.Nusch, A.Jerusalem, G.Chan, A.El Saghir, N.Alba, E.Im, S-A.Janni, W.Chandiwana, D.Lanoue, B.Thuerigen, A.Gaur, A.Harbeck, N.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26855enPooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)conference outputopen access10.1016/j.annonc.2020.08.3781569-8041http://www.annalsofoncology.org/article/S0923753420403746/pdf573469100276